vs
帕兰提尔科技（PLTR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
帕兰提尔科技的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），帕兰提尔科技净利率更高（43.3% vs 12.7%，领先30.5%），帕兰提尔科技同比增速更快（70.0% vs 5.9%），帕兰提尔科技自由现金流更多（$764.0M vs $161.8M），过去两年帕兰提尔科技的营收复合增速更高（48.9% vs 9.0%）
帕兰提尔科技是美国上市企业，专注研发数据集成与分析平台，为政府机构、军方及各行业企业提供多源数据整合分析能力。旗下核心产品Gotham与Foundry可打通相互孤立的数据库，广泛支撑情报作业、反恐分析、执法工作及企业级数据分析场景。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PLTR vs RVTY — 直观对比
营收规模更大
PLTR
是对方的1.8倍
$772.1M
营收增速更快
PLTR
高出64.2%
5.9%
净利率更高
PLTR
高出30.5%
12.7%
自由现金流更多
PLTR
多$602.2M
$161.8M
两年增速更快
PLTR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $608.7M | $98.4M |
| 毛利率 | 84.6% | — |
| 营业利润率 | 40.9% | 14.5% |
| 净利率 | 43.3% | 12.7% |
| 营收同比 | 70.0% | 5.9% |
| 净利润同比 | 670.4% | 3.9% |
| 每股收益（稀释后） | $0.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLTRRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $883.9M | $664.8M | ||
| Q4 24 | $827.5M | $729.4M | ||
| Q3 24 | $725.5M | $684.0M | ||
| Q2 24 | $678.1M | $691.7M | ||
| Q1 24 | $634.3M | $649.9M |
净利润PLTRRVTY
| Q4 25 | $608.7M | $98.4M | ||
| Q3 25 | $475.6M | $46.7M | ||
| Q2 25 | $326.7M | $53.9M | ||
| Q1 25 | $214.0M | $42.2M | ||
| Q4 24 | $79.0M | $94.6M | ||
| Q3 24 | $143.5M | $94.4M | ||
| Q2 24 | $134.1M | $55.4M | ||
| Q1 24 | $105.5M | $26.0M |
毛利率PLTRRVTY
| Q4 25 | 84.6% | — | ||
| Q3 25 | 82.4% | 53.6% | ||
| Q2 25 | 80.8% | 54.5% | ||
| Q1 25 | 80.4% | 56.5% | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 79.8% | 56.3% | ||
| Q2 24 | 81.0% | 55.7% | ||
| Q1 24 | 81.7% | 54.6% |
营业利润率PLTRRVTY
| Q4 25 | 40.9% | 14.5% | ||
| Q3 25 | 33.3% | 11.7% | ||
| Q2 25 | 26.8% | 12.6% | ||
| Q1 25 | 19.9% | 10.9% | ||
| Q4 24 | 1.3% | 16.3% | ||
| Q3 24 | 15.6% | 14.3% | ||
| Q2 24 | 15.5% | 12.4% | ||
| Q1 24 | 12.8% | 6.8% |
净利率PLTRRVTY
| Q4 25 | 43.3% | 12.7% | ||
| Q3 25 | 40.3% | 6.7% | ||
| Q2 25 | 32.6% | 7.5% | ||
| Q1 25 | 24.2% | 6.4% | ||
| Q4 24 | 9.5% | 13.0% | ||
| Q3 24 | 19.8% | 13.8% | ||
| Q2 24 | 19.8% | 8.0% | ||
| Q1 24 | 16.6% | 4.0% |
每股收益（稀释后）PLTRRVTY
| Q4 25 | $0.24 | $0.86 | ||
| Q3 25 | $0.18 | $0.40 | ||
| Q2 25 | $0.13 | $0.46 | ||
| Q1 25 | $0.08 | $0.35 | ||
| Q4 24 | $0.03 | $0.77 | ||
| Q3 24 | $0.06 | $0.77 | ||
| Q2 24 | $0.06 | $0.45 | ||
| Q1 24 | $0.04 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.2B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.4B | $7.3B |
| 总资产 | $8.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLTRRVTY
| Q4 25 | $7.2B | $919.9M | ||
| Q3 25 | $6.4B | $931.4M | ||
| Q2 25 | $6.0B | $991.8M | ||
| Q1 25 | $5.4B | $1.1B | ||
| Q4 24 | $5.2B | $1.2B | ||
| Q3 24 | $4.6B | $1.2B | ||
| Q2 24 | $4.0B | $2.0B | ||
| Q1 24 | $3.9B | $1.7B |
股东权益PLTRRVTY
| Q4 25 | $7.4B | $7.3B | ||
| Q3 25 | $6.6B | $7.4B | ||
| Q2 25 | $5.9B | $7.6B | ||
| Q1 25 | $5.4B | $7.6B | ||
| Q4 24 | $5.0B | $7.7B | ||
| Q3 24 | $4.5B | $7.9B | ||
| Q2 24 | $4.1B | $7.9B | ||
| Q1 24 | $3.8B | $7.8B |
总资产PLTRRVTY
| Q4 25 | $8.9B | $12.2B | ||
| Q3 25 | $8.1B | $12.1B | ||
| Q2 25 | $7.4B | $12.4B | ||
| Q1 25 | $6.7B | $12.4B | ||
| Q4 24 | $6.3B | $12.4B | ||
| Q3 24 | $5.8B | $12.8B | ||
| Q2 24 | $5.2B | $13.4B | ||
| Q1 24 | $4.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $777.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $764.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 54.3% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.28× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $509.4M |
8季度趋势，按日历期对齐
经营现金流PLTRRVTY
| Q4 25 | $777.3M | $182.0M | ||
| Q3 25 | $507.7M | $138.5M | ||
| Q2 25 | $539.3M | $134.3M | ||
| Q1 25 | $310.3M | $128.2M | ||
| Q4 24 | $460.3M | $174.2M | ||
| Q3 24 | $419.8M | $147.9M | ||
| Q2 24 | $144.2M | $158.6M | ||
| Q1 24 | $129.6M | $147.6M |
自由现金流PLTRRVTY
| Q4 25 | $764.0M | $161.8M | ||
| Q3 25 | $500.9M | $120.0M | ||
| Q2 25 | $531.6M | $115.5M | ||
| Q1 25 | $304.1M | $112.2M | ||
| Q4 24 | $457.2M | $149.8M | ||
| Q3 24 | $415.8M | $125.6M | ||
| Q2 24 | $141.3M | $136.6M | ||
| Q1 24 | $126.9M | $129.7M |
自由现金流率PLTRRVTY
| Q4 25 | 54.3% | 21.0% | ||
| Q3 25 | 42.4% | 17.2% | ||
| Q2 25 | 53.0% | 16.0% | ||
| Q1 25 | 34.4% | 16.9% | ||
| Q4 24 | 55.3% | 20.5% | ||
| Q3 24 | 57.3% | 18.4% | ||
| Q2 24 | 20.8% | 19.7% | ||
| Q1 24 | 20.0% | 20.0% |
资本支出强度PLTRRVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | 0.4% | 3.4% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.4% | 2.7% |
现金转化率PLTRRVTY
| Q4 25 | 1.28× | 1.85× | ||
| Q3 25 | 1.07× | 2.97× | ||
| Q2 25 | 1.65× | 2.49× | ||
| Q1 25 | 1.45× | 3.03× | ||
| Q4 24 | 5.83× | 1.84× | ||
| Q3 24 | 2.92× | 1.57× | ||
| Q2 24 | 1.08× | 2.87× | ||
| Q1 24 | 1.23× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLTR
| Geographic Concentration Risk | $1.1B | 77% |
| Other | $330.4M | 23% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
